# Nuclide record convergent-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/convergent-therapeutics/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "convergent-therapeutics" ;
  schema:name "Convergent Therapeutics"@en ;
  schema:description "Convergent Therapeutics attaches an alpha-emitting isotope to an antibody that homes in on prostate cancer cells, for men whose disease has progressed after standard radioligand treatment. Its lead medicine has reported mid-stage trial results."@en ;
  schema:url <https://nuclide.cc/companies/convergent-therapeutics/>, <http://convergentrx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <http://convergentrx.com/> ;
  schema:addressCountry "US" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioimmunotherapy/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06549465/> .